P2Y12 Receptor Function and Response to Cangrelor in Neonates With Cyanotic Congenital Heart Disease
| Autor: | Matthew Egalka, Hairu Zhou, Thomas G. Diacovo, Ruizhi Li, Elisabeth Kaza, Emile A. Bacha, Julie A. Vincent, Jayne Prats, Denise Evans, Scott L. Diamond, Jianchun Chen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
lcsh:Diseases of the circulatory (Cardiovascular) system
microfluidics 030204 cardiovascular system & hematology antithrombotic Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine P2Y12 Cangrelor avatar mice Antithrombotic medicine Platelet 030212 general & internal medicine Receptor business.industry medicine.disease Thrombosis neonates 3. Good health shunt thrombosis medicine.anatomical_structure chemistry lcsh:RC666-701 Anesthesia Conventional PCI Cardiology and Cardiovascular Medicine business Artery |
| Zdroj: | JACC. Basic to translational science JACC: Basic to Translational Science, Vol 2, Iss 4, Pp 465-476 (2017) |
| ISSN: | 2452-302X |
| Popis: | SUMMERY Shunt thrombosis remains a major cause of morbidity and mortality, especially during the initial palliation for single-ventricle physiology. The authors present evidence that the P2Y12 inhibitor cangrelor may fill a therapeutic void in thromboprophylaxis. They base this theory on results showing that platelets from neonatal patients with cyanotic congenital heart disease have a robust response to adenosine diphosphate and are amenable to P2Y12 inhibition with cangrelor. Unique to this study was their ability to establish drug efficacy in an avatar mouse model that permits the in vivo evaluation of human platelet–mediated thrombus formation illustrating that this P2Y12 inhibitor yields the intended biological response. Graphical abstract |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|